Better Buy Right Now: Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors.
One of those sectors may be healthcare, which is easy to understand. Because artificial intelligence (AI) has commanded the spotlight for the last several years and policy uncertainty swirls around that industry, it was easy for pharmaceutical stocks to slip under the radar.
That's why we'll look at two stocks that have climbed this year while the S 500 has slipped, to see if there's more momentum ahead. Those two are Johnson Johnson (NYSE: JNJ) and (NYSE: PFE).
Source Fool.com
Pfizer Inc. Stock
€23.05
-1.710%
We see a rather positive sentiment for Pfizer Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 29 € shows a positive potential of 25.81% compared to the current price of 23.05 € for Pfizer Inc..
